FDA Clears IND Application for Phase II Pulmonary Arterial Hypertension Trial
source: pixabay.com

FDA Clears IND Application for Phase II Pulmonary Arterial Hypertension Trial

According to a story from news.cision.com, the US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for CS1, an investigational drug being developed by the…

Continue Reading FDA Clears IND Application for Phase II Pulmonary Arterial Hypertension Trial
Study: The Effect of Patient Support Groups on Pulmonary Hypertension Patients and their Caregivers
rawpixel / Pixabay

Study: The Effect of Patient Support Groups on Pulmonary Hypertension Patients and their Caregivers

There are seven major categories of support groups including mental and emotional support, addiction, bereavement, or medical support. The latter groups are designed for patients according to a specific disease.…

Continue Reading Study: The Effect of Patient Support Groups on Pulmonary Hypertension Patients and their Caregivers
Generic Treprostinil for PAH Now Offers Subcutaneous Administration
whitesession / Pixabay

Generic Treprostinil for PAH Now Offers Subcutaneous Administration

  In 2019, generic pharmaceuticals and biosimilars leader Sandoz launched intravenous treprostinil for patients with pulmonary arterial hypertension (PAH). But according to a new media release, generic treprostinil is now…

Continue Reading Generic Treprostinil for PAH Now Offers Subcutaneous Administration
VerSIM Life Launched A Pharmaceutical Branch With A Rare Disease Mission
source: pixabay.com

VerSIM Life Launched A Pharmaceutical Branch With A Rare Disease Mission

As reported in Business Wire; VerSIM Life, a company that uses computational sciences to create novel machine learning to aid drug development, has announced that they are launching a pharmaceutical…

Continue Reading VerSIM Life Launched A Pharmaceutical Branch With A Rare Disease Mission

Researchers Work to Understand the Role of GDF15 in Lung Diseases Like Idiopathic Pulmonary Fibrosis

Growth differentiation factor 15 (GDF15) is expressed in normal conditions but is overly expressed when cells are under stress. It has multiple roles in different diseases and has been used…

Continue Reading Researchers Work to Understand the Role of GDF15 in Lung Diseases Like Idiopathic Pulmonary Fibrosis
DNMT3B Gene May Cause Pulmonary Hypertension, PAH Development
https://pixabay.com/en/stars-heart-love-mom-mother-443900/

DNMT3B Gene May Cause Pulmonary Hypertension, PAH Development

Recently, Pulmonary Hypertension News shared some burgeoning medical news: that the DNMT3B gene has now been linked to the development of pulmonary hypertension (PH) and a rare form of chronic high blood…

Continue Reading DNMT3B Gene May Cause Pulmonary Hypertension, PAH Development
Sotatercept for PAH Granted Orphan Designation from EC
https://pixabay.com/illustrations/cup-champion-award-trophy-winner-1613315/

Sotatercept for PAH Granted Orphan Designation from EC

In a recent press release, biopharmaceutical company Acceleron Pharma, Inc. ("Acceleron") announced that its investigational drug candidate sotatercept received Orphan designation from the European Commission (EC) for the treatment of…

Continue Reading Sotatercept for PAH Granted Orphan Designation from EC

Study: The Relationship Between Obesity, Lung Diseases, and Pulmonary Hypertension in Transplant Patients

The United States is coping with an obesity epidemic. It is therefore critical to understand the distribution of body fat and its effect on treatment. A recent article in Healio…

Continue Reading Study: The Relationship Between Obesity, Lung Diseases, and Pulmonary Hypertension in Transplant Patients
First Patient Dosed in Phase 1B Trial for Pulmonary Arterial Hypertension
https://pixabay.com/photos/animals-lemurs-wildlife-zoo-monkey-1010643/

First Patient Dosed in Phase 1B Trial for Pulmonary Arterial Hypertension

New Trial A Phase 1A trial for GMA301 was completed this year in Australia for pulmonary arterial hypertension (PAH). This trial demonstrated a positive safety profile for a range of…

Continue Reading First Patient Dosed in Phase 1B Trial for Pulmonary Arterial Hypertension
FDA Grants IDE to Test Experimental Device for Pulmonary Arterial Hypertension
source: pixabay.com

FDA Grants IDE to Test Experimental Device for Pulmonary Arterial Hypertension

According to a story from GlobeNewswire, the medical device company SoniVie announced recently that the US Food and Drug Administration (FDA) has granted approval for its Investigational Device Exemption (IDE).…

Continue Reading FDA Grants IDE to Test Experimental Device for Pulmonary Arterial Hypertension